[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f2n1o5ryctr2ue":5},{"data":4},[],{"data":6,"error":11},{"id":7,"documentId":8,"slug":9,"name":10,"medical_code":11,"short_description":12,"alternate_name":11,"disambiguating_description":11,"citations":13,"drugs":32,"specialties":39,"cover":11},916,"ij7nj3g9j5f6k31bqsuxbbqc","cytochrome-p450-3a-inhibitors","Cytochrome P450 3A Inhibitors",null,"CYP3A4 and CYP3A5 are the cytochrome P450 monooxygenases of the CYP3A subfamily that this class is named for: each inserts one atom of molecular oxygen into its substrate and reduces the second to water, with two electrons supplied by NADPH through cytochrome P450 reductase. CYP3A4 metabolises sterols, steroid hormones, retinoids and fatty acids; CYP3A5 metabolises steroid hormones and vitamins. Drugs in this class reduce that catalytic activity, so a co-administered drug cleared by CYP3A is eliminated more slowly and accumulates. FDA grades the consequence by how far a sensitive index substrate's exposure rises, calling an inhibitor strong at a 5-fold or greater increase in AUC and moderate at 2- to under 5-fold. A drug belongs here because its recorded effect on CYP3A is inhibition, not induction; as MED-RT populates the class its members include cobicistat, the protease inhibitors boceprevir, telaprevir, simeprevir and grazoprevir, idelalisib, osimertinib, letermovir, conivaptan, lomitapide, levoketoconazole and the ergot alkaloids.",[14,20,24,28],{"claims":15,"source":16,"licence":17,"source_url":18,"retrieved_at":19},"CYP3A4 as a cytochrome P450 monooxygenase metabolising sterols, steroid hormones, retinoids and fatty acids; 'uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase'.","UniProtKB P08684","not stated on source page","https:\u002F\u002Frest.uniprot.org\u002Funiprotkb\u002FP08684.json","2026-09-19",{"claims":21,"source":22,"licence":17,"source_url":23,"retrieved_at":19},"CYP3A5 as a cytochrome P450 monooxygenase 'involved in the metabolism of steroid hormones and vitamins'.","UniProtKB P20815","https:\u002F\u002Frest.uniprot.org\u002Funiprotkb\u002FP20815.json",{"claims":25,"source":26,"licence":17,"source_url":27,"retrieved_at":19},"'Strong and moderate inhibitors are drugs that increase the AUC of sensitive index substrates of a given metabolic pathway >=5-fold and >=2- to \u003C5-fold' - the FDA definition of an inhibitor, stated as a rise in substrate exposure.","FDA, Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers","https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers",{"claims":29,"source":30,"licence":17,"source_url":31,"retrieved_at":19},"Class membership: 27 ingredients including boceprevir, telaprevir, cobicistat, conivaptan, lomitapide, simeprevir, idelalisib, osimertinib, grazoprevir, safinamide, letermovir, levoketoconazole, ergotamine and dihydroergotamine.","RxNav RxClass class members (MED-RT), classId N0000190114","https:\u002F\u002Frxnav.nlm.nih.gov\u002FREST\u002Frxclass\u002FclassMembers.json?classId=N0000190114&relaSource=MEDRT&rela=has_MoA",[33],{"id":34,"documentId":35,"slug":36,"name":37,"active_ingredient":38,"dosage_form":11,"administration_route":11},1603,"kkutlv4pph1fgww8d7ofg78h","amlodipine","Amlodipine","Amlodipine besylate",[]]